Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OsteoNAFLD
NCT05493761Phase 4Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Dec 2022
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in non-alcoholic fatty liver disease (NAFLD) and osteoporosis (2 arms), sponsored by Aristotle University of Thessaloniki. Primary endpoint: Hepatic steatosis measured by Ultrasound-Guided Attenuation Parameter (UGAP) at 12 months. Started Dec 2022; status: completed.
02
Drugs
denosumab
03
Conditions
non-alcoholic fatty liver disease (NAFLD)osteoporosis
Beyond the preview
Go deeper on NCT05493761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493761.